Biotech and medical business blog

Visit BioHealth Investor

Cytokinetics & Amgen: positive heart failure drug without side effects? (CYTK, AMGN)

Posted on June 16, 2008

Cytokinetics Inc. (NASDAQ: CYTK) has presented data showing that its late trials of its CK-1827452 at the 2008 Heart Failure Congress of the European Society of Cardiology, which is being developed along with Amgen Inc. (NASDAQ: AMGN).The company announced positive results from an interim analysis of an ongoing Phase IIa clinical trial evaluating CK-1827452 intravenously [...]...

Original article link


clinical trial , phase